Chemotherapy of Colorectal Cancer: A Critical Analysis of Response Criteria and Therapeutic Efficacy

  • Alan Yagoda
  • Nancy Kemeny
Part of the Sloan-Kettering Institute Cancer Series book series (SKICS)


Large bowel cancer afflicts more patients in the United States than any other malignant neoplasm excluding skin cancer, is second only to lung cancer as a cause of cancer death, and accounts for 15% of all cancer deaths (Silverberg and Holleb, 1971). During the past 30 years there has been little change in the overall 5-year survival, 30% (Cutler, 1968), in patients who undergo “curative” surgical resection for colorectal cancer. These statistics are not surprising since almost half the patients with colorectal carcinoma have evidence of metastatic lymph node involvement at the time of surgery (Coller, 1956). While pre-and postoperative radiation therapy has permitted an increase in surgical resectability and overall palliation, it has not influenced 5-year survival rates. Obviously, other therapeutic modalities are needed.


Colorectal Cancer Hepatic Metastasis Partial Remission Cytosine Arabinoside Large Bowel Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Almersjo, O., Bengmark, S., Engevik, L., Hafstrom, L. O., and Nilsson, L. A. V., 1966, Hepatic artery ligation as pretreatment for liver resection of metastatic cancer, Rev. Surg. 23: 377–380.PubMedGoogle Scholar
  2. Ansfield, F., 1975, A randomized phase III study of four dosage regimens of 5-fluorouracil—A preliminary report (abstr. 1014), Proc. Am. Soc. Clin. Oncol. 16: 224.Google Scholar
  3. Ansfield, F., Schroeder, J. M., and Curreri, A. R., 1962, Five years experience with 5-fluorouracil, J. Am. Med. Assoc. 181: 295–297.CrossRefGoogle Scholar
  4. Ansfield, F., Ramirez, G., Skibba, J. L., Byran, G. T., Davis, H. L., Jr., and Wirtmen, G. W., 1971, Intrahepatic arterial infusion with-fluoruracil, Cancer 28: 1147–1158.PubMedCrossRefGoogle Scholar
  5. Ariel, I. M., and Briceno, M., 1976, The disparity of the liver size as determined by physical examination and by hepatic gammascanning in 504 patients, Med. Pediatr. Oncol. 2: 69–73.PubMedCrossRefGoogle Scholar
  6. Baker, L. H., Talley, R. W., Matier, R., Lehane, D. E., Ruffner, B. W., Jones, S. E., Morrison, F. S., Stephens, R. L., Gehan, E. A., and Vaitkevicius, V. K., 1976, Phase III comparison of the treatment of advanced gastrointestinal cancer with bolus weekly 5-FU vs. methyl CCNU plus bolus weekly 5-FU, Cancer 38: 1–6.PubMedCrossRefGoogle Scholar
  7. Bateman, J. R., 1974, Oral vs. intravenous administration of fluoroJ. Am. Med. Assoc. 229: 1109.Google Scholar
  8. Bateman, J. R., Pugh, R. P., Cassidy, E. R., Marshall, G. J., and Irwin, L. E., 1971, 5-Fluorouracil given once weekly: Comparison of intravenous and oral administration, Cancer 28: 907–913.Google Scholar
  9. Bengmark, S., and Hafstrom, L., 1969, The natural history of primary and secondary malignant tumors of the liver, Cancer 23: 198–202.PubMedCrossRefGoogle Scholar
  10. Bosch, L., Harbers, E., and Heidelberger, C., 1958, Studies of fluorinated pyrimidines vs. effects on nucleic acid metabolism in vitro, Cancer Res. 18: 335–343.PubMedGoogle Scholar
  11. Breedis, C., and Young, C., 1954, The blood supply of neoplasms in the liver, Am. J. Pathol. 30: 969–974.PubMedGoogle Scholar
  12. Cady, B., and Oberfield, R. A., 1974, Regional diffusion chemotherapy of hepatic metastases from carcinoma of colon, Am. J. Pathol. 127: 220–227.Google Scholar
  13. Carter, S. K., and Friedman, M., 1974, Integration of chemotherapy into combined modality treatment of solid tumors. II. Large bowel carcinoma, Cancer Treat. Rev. 1: 111–129.CrossRefGoogle Scholar
  14. Cedermark, B. J., Didolkar, M. S., and Elias, E. G., 1976, MethyICCNU (NSC-95441) in advanced colorectal carcinoma after failure of 5-fluorouracil (NSC-19893) therapy, Cancer Treat. Rep. 60: 235–238.PubMedGoogle Scholar
  15. Clarkson, R. B., O’Connor, A., Winston, L., and Hutchinson, D., 1964, The physiologic disposition of 5-fluorouracil and 5-fluoro-2’ deoxyuridine in man, Clin. Pharmacol. Ther. 5: 58 1610.Google Scholar
  16. Cohen, J. L., Irwin, L. E., Marshall, G. J., Darvey, H., and Bateman, J. R., 1974, Clinical pharmacology of oral and intravenous 5-fluorouracil (NSC-19893), Cancer Chemother. Rep. 58: 723–731.Google Scholar
  17. Coller, F. A., 1956, Cancer of the Colon and Rectum, p. 100, American Cancer Society, Inc., New York.Google Scholar
  18. Crooke, S. T., and Bradner, W. T., 1976, Mitomycin C: A review, Cancer Treat. Rev. 3: 121–139.PubMedCrossRefGoogle Scholar
  19. Cutler, S. J. 1968, End Results in Cancer,p. 47, Report No. 3, National Institutes of Health Publication No. 30, Washington, D.C.Google Scholar
  20. DeJager, R., Magill, G. B., Golbey, R. B., and Krakoff, I. H., 1974, Mitomycin C, 5-fluorouracil and cytosine arabinoside (MFC) in gastrointestinal cancer (abstr. 776), Proc. Am. Soc. Clin. Oncol. 15: 178.Google Scholar
  21. Douglass, H. O., Jr., and Mittleman, A., 1974, Metabolic studies of 5-fluorouracil-II influence of the route of administration on the dynamics of distribution in man, Cancer 34: 1878–1881.PubMedCrossRefGoogle Scholar
  22. Dwight, R. W., Humphrey, E. W., Higgins, G. A., and Keehn, R. J., 1973, FUDR as an adjuvant to surgery in cancer of the large bowel, J. Surg. Oncol. 5: 243–249.PubMedCrossRefGoogle Scholar
  23. Eastern Cooperative Group in Solid Tumor Chemotherapy, 1967, Comparison of antimetabolites in the treatment of breast and colon cancer, J. Am. Med. Assoc. 200: 770–778Google Scholar
  24. Engstrom, R., Catalano, R. B., and Creech, R. H., 1976, Phase II study of MeCCNU (NSC-95441) in advanced gastrointestinal cancer, Cancer Treat. Rep. 60: 285–287.PubMedGoogle Scholar
  25. Falkson, G., and Falkson, H., 1976, Fluorouracil, methyl-CCNU and vincristine in cancer of the colon, Cancer 38:1468–1470.Google Scholar
  26. Falkson, G., van Eden, E. B., and Falkson, H., 1974, Fluorouracil imadizole carboximide dimethyl triazeno, vincristine and bis-cholorethyl nitrosourea in colon cancer, Cancer 33: 1207–1209.PubMedCrossRefGoogle Scholar
  27. Frank, W., and Osterberg, A. E., 1960, Mitomycin C (NSC-26980): An evaluation of the Japanese reports, Cancer Chemother. Rep. 9:114–119Google Scholar
  28. Frytak, S., Moertel, C. G., Schutt, A. J., Hahn, R. G., and Reitmeier, R. J., 1975, Adriamycin (NSC-123127) therapy for advanced gastrointestinal cancers, Cancer Chemother. Rep. 59: 405–409.Google Scholar
  29. Gailani, S., Holland, J. F., Falkson, G., Leone, L., Burmingham, R., and Larsen, V., 1972, Comparison of treatment of metastatin gastrointestinal cancer with 5-fluorouracil (5-FU) to a combination of 5-FU with cytosine arabinoside, Cancer 29:1308–1314.Google Scholar
  30. Galante, M., Dunphy, J. E., and Fletcher, W. S., 1967, Cancer of the colon, Ann. Surg. 165: 732–744.PubMedCrossRefGoogle Scholar
  31. Golbey, R. B., Streeter, B., and Karnofsky, D. A., 1960, Clinical observations on patterns of cancer, Acta Un. Int. Cancr. 16: 1469–1472.PubMedGoogle Scholar
  32. Grage, T., Cornell, G., Strawitz, J., Jonas, K., Frelick, R., and Metter, G., 1975, Adjuvant therapy with 5-FU after surgical resection of colorectal cancer (abstr. 1149), Proc. Am. Soc. Clin. Oncol. 15: 258.Google Scholar
  33. Hahn, R. G., Moertel, C. G., Schutt, A. J., and Bruckner, H. W., 1975, A double-blind comparison of intensive course 5-fluorouracil by oral vs. intravenous route in the treatment of colorectal carcinoma, Cancer 35: 1031–1035.PubMedCrossRefGoogle Scholar
  34. Higgins, G. A., Swight, R. W., Smith, J. V., and Keehn, R., 1971, Fluorouracil as a adjuvant to surgery in carcinoma of the colon, Arch. Surg. 102: 339–343.PubMedCrossRefGoogle Scholar
  35. Higgins, G. A., Humphrey, E., Juler, G. L., LeVeen, H. H., McCaughan, J., and Keehn, R. J., 1976, Adjuvant chemotherapy in the surgical treatment of large bowel cancer, Cancer 38: 1461–1467.Google Scholar
  36. Holden, W. D., Dixon, W. J., and Kuzma, J. W., 1967, The use of triethylenethiophosphoramide as an adjuvant to the surgical treatment of colorectal carcinoma, Ann. Surg. 165: 481–503.PubMedCrossRefGoogle Scholar
  37. Horton, J. Olson, K. B., Sullivan, J., Reilly, C., and Shnider, B., 1970, The Eastern Cooperative Oncology Group, 1970, 5-fluorouracil in cancer: An improved regimen, Ann. Intern. Med. 73:897–900.Google Scholar
  38. Horton, J. Mittleman, A., Taylor, S. G., III, Jurkowitz, L., Bennett, J. M., Ezlini, E., Colsky, J. and Hanley, J. A., 1975, Phase II trials with procarbazine (NSC-77213), streptozotocin (NSC-85998), 6-thioguanine (NSC-752), and CCNU (NSC-79037) in patients with metastatic cancer of the large bowel, Cancer Chemother. Rep. 59:333–340.Google Scholar
  39. Hum, G. J., Bogdon, D. L., and Bateman, J. R., 1974, Phase I-II evaluation of weekly mitomycin C (NSC-26980) for patients with metastatic GI and breast malignancies, Oncology 30: 236–243.PubMedCrossRefGoogle Scholar
  40. Jacobs, E. M., Reeves, W. J., Wood, D. A., Pugh, R., Braunwald, J., and Bateman, J. R., 1971, Treatment of cancer with weekly intravenous 5-fluorouracil, Cancer 27: 1302–1305.PubMedCrossRefGoogle Scholar
  41. Karnofsky, D. A., 1961, Meaningful clinical classification of therapeutic responses to anticancer drugs, Clin. Pharmacol. Ther. 2: 709–721.PubMedGoogle Scholar
  42. Karnofsky, D. A., Ellison, R. R., and Golbey, R. B., 1962, Selection of patients for evaluation of chemotherapeutic procedures in advanced cancer, Cancer Chemother. Rep. 16: 73–77.PubMedGoogle Scholar
  43. Khung, C. L., Hall, T. C., Piro, A. J., and Dederick, M. M., 1966, A clinical trial of oral 5-fluorouracil, Clin. Pharmacol. Ther. 7: 527–553.PubMedGoogle Scholar
  44. Kim, P. N., DeMattia, M., Buroker, T., and Vaitkevicius, V. K., 1975, Mitomycin C alone and in combination with infused 5-fluorouracil in treatment of disseminated gastrointestinal carcinomas (abstr. 1039), Proc. Am. Soc. Clin. Oncol. 15: 230.Google Scholar
  45. Kovach, J. S., Moertel, C. G., Schutt, A. J., Reitmejer, R. G., and Hahn, R. G., 1973, Phase II study of cis-diamminedichloroplatinum (NSC-119875) in advanced carcinoma of the large bowel, Cancer Chemother. Rep. 57: 357–360.PubMedGoogle Scholar
  46. Krakoff, I. H., 1972, Chemotherapy of gastrointestinal cancer, Cancer 30: 1600–1603.PubMedCrossRefGoogle Scholar
  47. Lahiri, S. R., Bioleau, G., and Hall, T. C., 1971, Treatment of metastatic colorectal carcinoma with 5-fluorouracil by mouth, Cancer 28: 902–906.PubMedCrossRefGoogle Scholar
  48. Lawrence, W. Jr., Terz, J. J. Horsley, J. S. II, King, R. E., Lovett, W. L., Brown, P. W., Ruffner, B. B., and -Regelson, W., 1975, Chemotherapy as an adjuvant to surgery for coloraectal cancer, Ann. Surg. 181:616–623Google Scholar
  49. Lemon, H. M., 1960, Reduction of 5-fluorouracil toxicity in man, with retention of anticancer effects by prolonged intravenous administration in 5% dextrose, Cancer Chemother. Rep. 8: 97–101.PubMedGoogle Scholar
  50. Lemon, H. M., and Foley, J. F., 1966, Antimetabolite therapy of advanced carcinoma and sarcoma, in: Controversy in Internal Medicine (F. J., Ingelfinger, A. S. Relman, and M. Finland, eds.), pp. 575–590, Saunders, Philadelphia.Google Scholar
  51. Li, M. C., and Ross, S. T., 1976, Chemoprophylaxis for patients with colorectal cancer— Prospective study with five-year follow-up, J. Am. Med. Assoc. 235: 2825–2828.CrossRefGoogle Scholar
  52. Livingston, R. B., and Carter, S. K., 1970, Single Agents in Cancer Chemotherapy, Plenum, New York.CrossRefGoogle Scholar
  53. Mackman, S., and Curreri, A. R., 1968, The second-look operation for cancer of the colon after administration of 5-fluorouracil, 1968, Am J . Surg. 115: 227–230.PubMedCrossRefGoogle Scholar
  54. Mackman, S., Ansfield, F. J., Ramirez, G., and Curreri, A. R., 1974, A second look at the second-look operation in colonic cancer after the administration of 5-fluorouracil, Ann J . Surg. 128: 763–766.Google Scholar
  55. Mavligit, G. M., Gutteramn, J. U., Burgess, M. A., Khankanian, N., Seibert, G. B., Speer, J. F., Jubert, A. V., Martin, R., McBride, C. M., Copeland, E. M., and Gehan, E. A., 1976, Prolongation of post-operative disease-free interval and survival in human colorectal cancer by BCG or GCG plus 5-FU, Lancet 1(7965):871–876 Google Scholar
  56. Moertel, C. G., 1973, Therapy of advanced gastrointestinal cancer with the nitrosoureas, Cancer Chemother. Rep. Part 3 4: 27–34.Google Scholar
  57. Moertel, C. G., 1975, Chemotherapy of gastrointestinal cancer: State of the art in 1975, Int. J. Radiat. Oncol. Biol. Phys. 1: 169–171.PubMedCrossRefGoogle Scholar
  58. Moertel, C. G., 1976, Gastrointestinal cancer—Treatment with fluorouracil-nitrosourea combinations, J. Am. Med. Assoc. 235: 2135–2136.CrossRefGoogle Scholar
  59. Moertel, C. G., and Hanley, J. A., 1976, The effect of measuring error on the results of therapeutic trials in advanced cancer, Cancer 38: 388–394.PubMedCrossRefGoogle Scholar
  60. Moertel, C. G., and Reitemeier, R. J., 1962, Experience with 5-fluorouracil in the palliative management of advanced carcinoma of the gastrointestinal tract, Proc. Mayo Clin. 37: 520–526.Google Scholar
  61. Moertel, C. G., and Reitemeier, R. J., 1969, Advanced Gastrointestinal cancer—Clinical Management and Chemotherapy, Harper and Row, New York.Google Scholar
  62. Moertel, C. G., Reitemeier, R. J., and Hahn, R. G., 1968, Mitomycin C therapy in advanced gastrointestinal cancer, J. Am. Med. Assoc. 204: 1045–1048.Google Scholar
  63. Moertel, C. G., Reitemeier, R. J., and Hahn, R. G., 1970, Oral methotrexate therapy of gastrointestinal carcinoma, Surg. Gynecol. Obstet. 130: 292–294.Google Scholar
  64. Moertel, C. G., Schutt, A. J., Reitemeier, R. J., and Hahn, R. G., 1972, A comparison of 5-fluorouracil administered by slow infusion and rapid injection, Cancer Res. 32: 2717–2719.Google Scholar
  65. Moertel, C. G., Schutt, A. J. Hahn, R. G., and Reitmeier, R. J., 1974, Effects of patient selection on results of phase II chemotherapy trials in gastrointestinal cancer, Cancer Chemother. Rep. 58: 257–259.Google Scholar
  66. Moertel, C. G., Schutt, A. J., Hahn, R. G., and Reitmeier, R. J., 1975, Brief communication: Therapy of advanced colorectal cancer with a combination of 5-fluorouracil, methyl-1,2 cis(2-chlorethyl)-1-nitrosourea, and vincristins, J. Natl. Cancer Inst. 54: 66–71.Google Scholar
  67. Moore, G. E., Bross, I. D. J., Ansman, R., Nadler, S., Jones, R., Jr., Slack, N., and Rimm, A. A., 1968, Effects of mitomycin C in 346 patients with advanced cancer, Cancer Chemother. Rep. 52: 675–684.Google Scholar
  68. Mukherjee, K. L., Boohar, J., Wentland, D., Ansfield, F. J., and Heidelberger, C., 1963, Studies on fluorinated pyrimidines. XVI. Metabolism of 5-fluorouracil-2-C and 5fluor-2-deoxyuridine-2-C in cancer patients, Cancer Res. 23: 49–66.Google Scholar
  69. Neilsen, J., Balsley, J., and Jensen, H. E., 1971, Carcinoma of the colon with liver metastasis, Acta Chir. Sismol. 137:463–471.Google Scholar
  70. Nilsson, L. A. V., 1966, Therapeutic hepatic artery ligation in patients with secondary liver tumors, Rev. Surg. 374:6.Google Scholar
  71. Ota, K., Kurita, S., Nishimura, M., Kamei, Y., Imai, K., Ariyoshi, Y., Kataoka, K., Murakami, M., Oyama, A., Hoshino, A., Amo, H., and Kato, T., 1972, Combination therapy with mitomycin D, 5-fluorouracil, and cytosine arabinoside for advanced cancer in man, Cancer Chemother. Rep. 56: 383–385.Google Scholar
  72. Pestana, C., Reitmeier, R. J., Moertel, C. G., Judd, E. S., and Dockerty, M. B., 1964, The natural history of carcinoma of the colon and rectum, Am. J. Surg. 108: 826–829.PubMedCrossRefGoogle Scholar
  73. Ramiraz, G., Korbitz, B. C., Davis, H. L., Jr., and Ansfield, F. J., 1969, Cancer Chemother. Rep. 53: 243–247.Google Scholar
  74. Reitemeier, R. J., Moertel, C. G., and Hahn, R. G., 1970, Combination chemotherapy in gastrointestinal cancer, Cancer Res. 30: 1425–1428.PubMedGoogle Scholar
  75. Rousselot, L. M., Cole, D. R., Grosse, C. E., Conte, A. J., Gonzelez, E. M., and Pasternak, B. S., 1968, A five year progress report on the effectiveness of intraluminal chemotherapy (5fluorouracil) adjuvant to surgery for colorectal cancer, Am. J. Surg.115:140–147.Google Scholar
  76. Rousselot, L. M., Cole, D. R., Grossi, C. E., Conte, A. J. Gonzalez, E. M., and Pasternack, B. S., 1972, Adjuvant chemotherapy with 5-fluorouracil in surgery for colorectal cancer: Eight-year report, Dis. Colon Rectum 15(3):169–174.Google Scholar
  77. Rytand, D. A., 1968, The midclavicular line: Where is it?, Ann. Intern. Med. 70: 329–330.CrossRefGoogle Scholar
  78. Schoftenfeld, D., 1971, Statistical Report of End Results 1949–1954, 1955–1959, 1960–1964, pp. 32–33, 38–39, Memorial Hospital for Cancer and Allied Diseases, New York.Google Scholar
  79. Schutt, A. J., Hahn, R. G., Reitmeier, R. J., and Moertel, C. G., 1973, A phase II study of intermittent high-dose cyclophosphamide therapy of advanced gastrointestinal cancer,Cancer Res. 33: 2218–2220.Google Scholar
  80. Seifert, P., Baker, L. H., Reed, M. L., and Vaitkevicius, V. K., 1975, Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma, Cancer 36:123–138.Google Scholar
  81. Silverberg, E., and Holleb, A. I., 1971, Cancer statistics, Cancer 21: 13–31.Google Scholar
  82. Slavik, M., 1976, Clinical studies with DTIC in various malignancies, Cancer Treat. Rep. 60: 213–214.PubMedGoogle Scholar
  83. Sullivan, R. D., Miller, E., Zurek, W. Z., Oberfield, R. A., and Ojima, Y., 1967, Re-evaluation of methotrexate as an anticancer drug, Surg. Gynecol. Obstet. 127: 819–824.Google Scholar
  84. Vaughn, C. B., Chinn, B. J., Deversa, B., and Parzuchowski, J., 1975, Comparison of combination chemotherapy in advanced gastrointestinal malignancy: 5-Fluorouracil plus mitomycin C vs. 5-fluorouracil plus 1-(2 1-(2 chloroethyl) 3-(4 methylcyclohexyl)-1-nitrosourea, 1975 (abstr. 1126), Proc. Am. Soc. Clin. Oncol. 16: 252.Google Scholar
  85. Wasserman, T. H., Slavik, M., and Carter, S. K., 1975, Clinical comparison of the nitrosoureas, Cancer 36: 1258–1268.PubMedCrossRefGoogle Scholar
  86. Watkins, E. Jr., Khazei, A. M., and Nahra, K. S., 1970, Surgical basis for arterial infusion chemotherapy of disseminated carcinoma of the liver, Surg. Gynecol. Obstet. 130: 581–605.PubMedGoogle Scholar
  87. Wilson, S. M., and Adson, M. A., 1976, Surgical treatment of hepatic metastases from colorectal cancers, Arch. Surg. 111: 330–334.PubMedCrossRefGoogle Scholar
  88. Wood, C. B., Gillis, C. R., and Blumgart, L. H., 1976, A retrospective study of the natural history of patients with liver metastases from colorectal cancer, Clin. Oncol. 2: 285–288.PubMedGoogle Scholar
  89. Woolley, P. V., III, MacDonald, J. S., and Schein, P. S., 1976, Chemotherapy of colorectal carcinoma, Sem. Oncol. 3: 415–420.Google Scholar
  90. Yagoda, A., Lippman, A., Winn, R., Rosenberg, A., and Schulman, P., 1974, Mitomycin C, 5-FU and cytosine arabinoside (MiFuCa) in adenocarcinomas (abstr. 826), Proc. Am. Soc. Clin. Oncol. 15: 190.Google Scholar
  91. Young, C. W., Ellison, R. R., Sullivan, R. D., Levick, S. N., Kaufman, R., Miller, E., Woldow, I., Escher, G., Li, M. C., Karnofsky, D. A., and Burchenal, J. H., 1960, The clinical evaluation of 5-fluorouracil and 5-fluoro-2’-deoxyuridine in solid tumors in adults: A progress report, Cancer Chemother Rep. 6: 17–19.PubMedGoogle Scholar
  92. Zubrod, C. G., 1966, The limited usefulness of 5-fluorouracil (5-FU) and 5-fluorodeoxyuridine (5-FUDR) in the management of patients with adenocarcinoma, in: Controversy in Internal Medicine ( F. J. Ingelfinger, A. S. Relman, and M. Finland, eds.), pp. 591–600, Saunders, Philadelphia.Google Scholar

Copyright information

© Springer Science+Business Media New York 1978

Authors and Affiliations

  • Alan Yagoda
    • 1
  • Nancy Kemeny
    • 1
  1. 1.Assistant Attendings, Solid Tumor Service, Department of MedicineMemorial Sloan-Kettering Cancer CenterNew YorkUSA

Personalised recommendations